AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
ClinicalTrials.gov Studies
Summary
NIH's ClinicalTrials.gov has registered NCT07538882, a prospective observational study evaluating an AI model's ability to assist clinical physicians in staging hepatocellular carcinoma (HCC) and making treatment decisions. The Multi-Rater Multi-Case crossover study will compare physician accuracy under unassisted versus AI-assisted conditions across different hospital tiers to determine whether AI can reduce diagnostic and therapeutic heterogeneity in HCC care.
What changed
A prospective observational study evaluating a self-developed AI model for hepatocellular carcinoma staging and treatment decision-making has been registered on ClinicalTrials.gov. The study will recruit HCC patients and clinical physicians across different hospital tiers using a Multi-Rater Multi-Case crossover balanced design, comparing physician accuracy under unassisted versus AI-assisted evaluation conditions across CNLC, TNM, and BCLC staging systems.
Healthcare providers and clinical investigators should note this trial as a marker of growing interest in AI-assisted cancer staging. The study focuses on whether AI assistance can enhance physician capabilities in primary and secondary care settings, potentially informing future clinical decision support implementations.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Observational NCT07538882 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
The precise treatment of primary hepatocellular carcinoma (HCC) highly depends on accurate disease staging (CNLC, TNM, BCLC) and scientific treatment decision-making, which necessitate the integration of both imaging and clinical baseline data. This study prospectively recruits HCC patients and clinical physicians across different hospital tiers to evaluate the clinical value of a self-developed artificial intelligence (AI) model in assisting multi-dimensional comprehensive assessment and treatment decision-making. Utilizing a Multi-Rater Multi-Case (MRMC) crossover balanced design, the study compares the accuracy of clinical evaluations performed by physicians under "unassisted (without AI)" versus "AI-assisted" conditions. A key focus is to explore whether AI can significantly enhance the comprehensive assessment capabilities of physicians in primary/secondary care hospitals, thereby prospectively reducing diagnostic and therapeutic heterogeneity across different institutional levels.
Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Unassisted Independent Evaluation, AI-Assisted Evaluation
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.